Covered recipient · General Payments record
MONIKA FISCHER
Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2023 · Entire year
$43,116.76
69 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2023 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $30,185.00 | 8 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3,967.00 | 3 |
| Travel and Lodging | $3,730.44 | 13 |
| Honoraria | $3,250.00 | 1 |
| Food and Beverage | $1,928.37 | 43 |
| Education | $55.95 | 1 |
By paying entity
PY2023 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Ferring Pharmaceuticals Inc. | $19,995.01 | 15 |
| E.R. Squibb & Sons, L.L.C. | $8,989.98 | 8 |
| Janssen Biotech, Inc. | $5,256.22 | 5 |
| AIMMUNE THERAPEUTICS, INC. | $3,334.86 | 4 |
| Eli Lilly and Company | $2,140.57 | 8 |
| Lilly USA, LLC | $1,618.00 | 4 |
| Rebiotix Inc. | $800.00 | 1 |
| ABBVIE INC. | $586.85 | 17 |
| Celgene Corporation | $310.26 | 2 |
| Takeda Pharmaceuticals U.S.A., Inc. | $64.57 | 4 |
| Janssen Scientific Affairs, LLC | $20.44 | 1 |
Page 2 of 2; records 51–69 of 69 matching records. This page contains 19 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
MONIKA FISCHER
NPI 1023264900 · CMS profile ID 318170
Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology
INDIANAPOLIS, IN
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–69 of 69 matching records. This page contains 19 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1023264900?year=2023&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- MONIKA FISCHER, NPI 1023264900, CMS profile ID 318170. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–69 of 69 matching records. This page contains 19 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1023264900?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- APA 7
- IndustryPayments. (2026). MONIKA FISCHER, NPI 1023264900, CMS profile ID 318170. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–69 of 69 matching records. This page contains 19 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1023264900?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- Bluebook
- MONIKA FISCHER, NPI 1023264900, CMS profile ID 318170, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–69 of 69 matching records. This page contains 19 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1023264900?year=2023&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2023
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30
69 matching records · $43,116.76 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–69 of 69.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Ferring Pharmaceuticals Inc. | $410.81 | 04/28/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1044145239 | CMS |
| Ferring Pharmaceuticals Inc. | $63.49 | 04/28/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1044145253 | CMS |
| Ferring Pharmaceuticals Inc. | $40.00 | 04/28/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1044145267 | CMS |
| Ferring Pharmaceuticals Inc. | $175.91 | 04/28/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1044145281 | CMS |
| Ferring Pharmaceuticals Inc. | $410.55 | 04/28/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1044145295 | CMS |
| E.R. Squibb & Sons, L.L.C. | $315.72 | 04/14/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1014990285 | CMS |
| E.R. Squibb & Sons, L.L.C. | $461.35 | 04/13/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1014990293 | CMS |
| AIMMUNE THERAPEUTICS, INC. | $3,250.00 | 04/06/2023 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 998920639 | CMS |
| E.R. Squibb & Sons, L.L.C. | $55.95 | 04/05/2023 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1014989961 | CMS |
| Lilly USA, LLC | $800.00 | 04/03/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031981107 | CMS |
| ABBVIE INC. | $29.80 | 03/30/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 997254459 | CMS |
| ABBVIE INC. | $24.34 | 03/24/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 997254457 | CMS |
| Janssen Scientific Affairs, LLC | $20.44 | 03/02/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 988459731 | CMS |
| ABBVIE INC. | $77.50 | 02/22/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 997254455 | CMS |
| Lilly USA, LLC | $800.00 | 02/21/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1031921835 | CMS |
| Rebiotix Inc. | $800.00 | 02/09/2023 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1044333485 | CMS |
| Janssen Biotech, Inc. | $15.80 | 02/07/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 988163689 | CMS |
| Celgene Corporation | $10.26 | 02/02/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1014989991 | CMS |
| ABBVIE INC. | $26.36 | 01/06/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 997254453 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $592,426.82 | 86 |
| PY2024 | Principal investigator | $390,227.66 | 45 |
| PY2023 | Principal investigator | $267,004.34 | 29 |
| PY2022 | Principal investigator | $556,853.49 | 17 |
| PY2021 | Principal investigator | $307,777.81 | 13 |
| PY2020 | Recipient | $11.46 | 1 |
| PY2020 | Principal investigator | $148,338.60 | 10 |
| PY2019 | Recipient | $960.00 | 1 |
| PY2019 | Principal investigator | $291,799.41 | 14 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
86 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | F. Hoffmann-La Roche AG | $1,699.00 | 12/19/2025 | Non-covered Recipient Entity Indiana University | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211614525 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,910.66 | 12/19/2025 | Covered Recipient Teaching Hospital INDIANA UNIVERSITY HEALTH | A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease | Dispute reported | 06/30/2026 | 1223266963 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $13,156.00 | 12/11/2025 | Non-covered Recipient Entity Indiana University | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211614522 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $3,000.00 | 12/11/2025 | Non-covered Recipient Entity Indiana University | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211614529 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $15,200.00 | 12/11/2025 | Non-covered Recipient Entity Indiana University | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211614536 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $10,462.00 | 12/04/2025 | Non-covered Recipient Entity Indiana University | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211614533 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $7,000.00 | 12/04/2025 | Covered Recipient Teaching Hospital INDIANA UNIVERSITY HEALTH | ENTYVIO (VEDOLIZUMAB) LONG-TERM SAFETY STUDY: AN INTERNATIONAL OBSERVATIONAL PROSPECTIVE COHORT STUDY COMPARING VEDOLIZUMAB TO OTHER BIOLOGIC AGENTS IN PATIENTS WITH ULCERATIVE COLITIS OR CROHN'S DISEASE | Dispute reported | 06/30/2026 | 1223266949 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,000.00 | 12/04/2025 | Covered Recipient Teaching Hospital INDIANA UNIVERSITY HEALTH | ENTYVIO (VEDOLIZUMAB) LONG-TERM SAFETY STUDY: AN INTERNATIONAL OBSERVATIONAL PROSPECTIVE COHORT STUDY COMPARING VEDOLIZUMAB TO OTHER BIOLOGIC AGENTS IN PATIENTS WITH ULCERATIVE COLITIS OR CROHN'S DISEASE | Dispute reported | 06/30/2026 | 1223266951 |
| Principal investigator 1 | Genentech, Inc. | $3,176.00 | 11/25/2025 | Non-covered Recipient Entity Indiana University | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211614583 |
| Principal investigator 1 | Genentech, Inc. | $1,030.00 | 11/25/2025 | Non-covered Recipient Entity Indiana University | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211614587 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $4,780.94 | 11/25/2025 | Covered Recipient Teaching Hospital INDIANA UNIVERSITY HEALTH | A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease | Dispute reported | 06/30/2026 | 1223266947 |
| Principal investigator 1 | Genentech, Inc. | $6,689.00 | 11/14/2025 | Non-covered Recipient Entity Indiana University | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211614575 |
| Principal investigator 1 | Genentech, Inc. | $3,456.00 | 11/07/2025 | Non-covered Recipient Entity Indiana University | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211614579 |
| Principal investigator 1 | Genentech, Inc. | $2,980.00 | 10/29/2025 | Non-covered Recipient Entity Indiana University | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211614571 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $4,150.58 | 10/29/2025 | Covered Recipient Teaching Hospital INDIANA UNIVERSITY HEALTH | A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease | Dispute reported | 06/30/2026 | 1223266935 |
| Principal investigator 1 | ABBVIE INC. | $1,000.00 | 10/15/2025 | Non-covered Recipient Entity INDIANA UNIVERSITY | A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1202516983 |
| Principal investigator 1 | ABBVIE INC. | $5,837.12 | 10/09/2025 | Non-covered Recipient Entity INDIANA UNIVERSITY | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202515763 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $632.00 | 10/08/2025 | Covered Recipient Teaching Hospital INDIANA UNIVERSITY HEALTH | A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL | Dispute reported | 06/30/2026 | 1223266927 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $632.00 | 10/08/2025 | Covered Recipient Teaching Hospital INDIANA UNIVERSITY HEALTH | A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL | Dispute reported | 06/30/2026 | 1223266929 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,329.27 | 10/03/2025 | Covered Recipient Teaching Hospital INDIANA UNIVERSITY HEALTH | A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease | Dispute reported | 06/30/2026 | 1223266925 |
| Principal investigator 1 | Eli Lilly and Company | $8,200.00 | 10/02/2025 | Non-covered Recipient Entity INDIANA UNIVERSITY | MIRIKIZUMAB LY3074828 PRO UC CD - OMVOH - ULCERATIVE COLITIS | No dispute reported | 06/30/2026 | 1187881582 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $104.00 | 09/23/2025 | Non-covered Recipient Entity Indiana University | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211614498 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $450.00 | 09/23/2025 | Non-covered Recipient Entity Indiana University | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211614510 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $3,252.00 | 09/23/2025 | Non-covered Recipient Entity Indiana University | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211614518 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,451.67 | 09/23/2025 | Covered Recipient Teaching Hospital INDIANA UNIVERSITY HEALTH | A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease | Dispute reported | 06/30/2026 | 1223266915 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $10,669.00 | 09/23/2025 | Covered Recipient Teaching Hospital INDIANA UNIVERSITY HEALTH | A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease | Dispute reported | 06/30/2026 | 1223266917 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $15,200.00 | 09/23/2025 | Covered Recipient Teaching Hospital INDIANA UNIVERSITY HEALTH | A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease | Dispute reported | 06/30/2026 | 1223266919 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,836.00 | 09/23/2025 | Covered Recipient Teaching Hospital INDIANA UNIVERSITY HEALTH | A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease | Dispute reported | 06/30/2026 | 1223266921 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,000.00 | 09/23/2025 | Covered Recipient Teaching Hospital INDIANA UNIVERSITY HEALTH | A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease | Dispute reported | 06/30/2026 | 1223266923 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,044.09 | 09/18/2025 | Covered Recipient Teaching Hospital INDIANA UNIVERSITY HEALTH | A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease | Dispute reported | 06/30/2026 | 1223266911 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $632.00 | 09/15/2025 | Covered Recipient Teaching Hospital INDIANA UNIVERSITY HEALTH | A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL | Dispute reported | 06/30/2026 | 1223266905 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $10,868.98 | 09/12/2025 | Covered Recipient Teaching Hospital INDIANA UNIVERSITY HEALTH | A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease | Dispute reported | 06/30/2026 | 1223266903 |
| Principal investigator 1 | ABBVIE INC. | $37,523.76 | 09/04/2025 | Non-covered Recipient Entity INDIANA UNIVERSITY | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202509766 |
| Principal investigator 1 | ABBVIE INC. | $13,042.40 | 09/04/2025 | Non-covered Recipient Entity INDIANA UNIVERSITY | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202509768 |
| Principal investigator 1 | ABBVIE INC. | $5,500.00 | 09/04/2025 | Non-covered Recipient Entity INDIANA UNIVERSITY | A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1202509770 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,451.67 | 09/04/2025 | Covered Recipient Teaching Hospital INDIANA UNIVERSITY HEALTH | A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease | Dispute reported | 06/30/2026 | 1223266901 |
| Principal investigator 1 | ABBVIE INC. | $24,752.00 | 09/03/2025 | Non-covered Recipient Entity INDIANA UNIVERSITY | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202508170 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $3,000.00 | 08/07/2025 | Non-covered Recipient Entity Indiana University | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211614494 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $9,656.00 | 08/07/2025 | Non-covered Recipient Entity Indiana University | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211614502 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $3,500.00 | 08/07/2025 | Non-covered Recipient Entity Indiana University | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211614506 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $15,200.00 | 08/07/2025 | Non-covered Recipient Entity Indiana University | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211614514 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,451.67 | 08/07/2025 | Covered Recipient Teaching Hospital INDIANA UNIVERSITY HEALTH | A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease | Dispute reported | 06/30/2026 | 1223266891 |
| Principal investigator 1 | ABBVIE INC. | $11,772.16 | 08/06/2025 | Non-covered Recipient Entity INDIANA UNIVERSITY | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202503033 |
| Principal investigator 1 | ABBVIE INC. | $6,089.39 | 08/06/2025 | Non-covered Recipient Entity INDIANA UNIVERSITY | A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1202503035 |
| Principal investigator 1 | ABBVIE INC. | $15,917.76 | 07/31/2025 | Non-covered Recipient Entity INDIANA UNIVERSITY | A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1202500674 |
| Principal investigator 1 | ABBVIE INC. | $22,876.00 | 07/31/2025 | Non-covered Recipient Entity INDIANA UNIVERSITY | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202500676 |
| Principal investigator 1 | Eli Lilly and Company | $1,014.88 | 07/28/2025 | Non-covered Recipient Entity INDIANA UNIVERSITY | A PHASE 3B, RANDOMIZED, MULTICENTER, CONTROLLED STUDY OF MIRIKIZUMAB AND PLACEBO OR MIRIKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS AND OBESITY OR OVERWEIGHT | No dispute reported | 06/30/2026 | 1187882056 |
| Principal investigator 1 | Eli Lilly and Company | $942.88 | 07/28/2025 | Non-covered Recipient Entity INDIANA UNIVERSITY | A PHASE 3B, RANDOMIZED, MULTICENTER, CONTROLLED STUDY OF MIRIKIZUMAB AND PLACEBO OR MIRIKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE AND OBESITY OR OVERWEIGHT | No dispute reported | 06/30/2026 | 1187882846 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $1,300.00 | 07/22/2025 | Non-covered Recipient Entity Indiana University | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211614489 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $13,913.07 | 07/22/2025 | Covered Recipient Teaching Hospital INDIANA UNIVERSITY HEALTH | A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Treatment of Adult Participants With Moderately to Severely Active Crohns Disease | Dispute reported | 06/30/2026 | 1223266881 |
| Principal investigator 1 | ABBVIE INC. | $2,860.08 | 07/02/2025 | Non-covered Recipient Entity INDIANA UNIVERSITY | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202495599 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,639.00 | 06/25/2025 | Covered Recipient Teaching Hospital INDIANA UNIVERSITY HEALTH | A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET | Dispute reported | 06/30/2026 | 1223266879 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,400.00 | 06/18/2025 | Covered Recipient Teaching Hospital INDIANA UNIVERSITY HEALTH | A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL | Dispute reported | 06/30/2026 | 1223266875 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $110.00 | 06/18/2025 | Covered Recipient Teaching Hospital INDIANA UNIVERSITY HEALTH | A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL | Dispute reported | 06/30/2026 | 1223266877 |
| Principal investigator 1 | ABBVIE INC. | $2,300.00 | 06/09/2025 | Non-covered Recipient Entity INDIANA UNIVERSITY | A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1202490651 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $632.00 | 06/06/2025 | Covered Recipient Teaching Hospital INDIANA UNIVERSITY HEALTH | A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL | Dispute reported | 06/30/2026 | 1223266871 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $632.00 | 06/06/2025 | Covered Recipient Teaching Hospital INDIANA UNIVERSITY HEALTH | A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL | Dispute reported | 06/30/2026 | 1223266873 |
| Principal investigator 1 | ABBVIE INC. | $16,378.48 | 06/03/2025 | Non-covered Recipient Entity INDIANA UNIVERSITY | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202488335 |
| Principal investigator 1 | Eli Lilly and Company | $7,108.00 | 05/27/2025 | Non-covered Recipient Entity INDIANA UNIVERSITY | A PHASE 3, MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS LUCENT 3 | No dispute reported | 06/30/2026 | 1187881580 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $5,000.00 | 05/16/2025 | Covered Recipient Teaching Hospital INDIANA UNIVERSITY HEALTH | A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET | Dispute reported | 06/30/2026 | 1223266859 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,500.00 | 05/16/2025 | Covered Recipient Teaching Hospital INDIANA UNIVERSITY HEALTH | A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET | Dispute reported | 06/30/2026 | 1223266861 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $800.00 | 05/16/2025 | Covered Recipient Teaching Hospital INDIANA UNIVERSITY HEALTH | A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET | Dispute reported | 06/30/2026 | 1223266863 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,750.00 | 05/16/2025 | Covered Recipient Teaching Hospital INDIANA UNIVERSITY HEALTH | A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET | Dispute reported | 06/30/2026 | 1223266865 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $574.00 | 05/16/2025 | Covered Recipient Teaching Hospital INDIANA UNIVERSITY HEALTH | A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET | Dispute reported | 06/30/2026 | 1223266867 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $10,492.00 | 05/16/2025 | Covered Recipient Teaching Hospital INDIANA UNIVERSITY HEALTH | A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET | Dispute reported | 06/30/2026 | 1223266869 |
| Principal investigator 1 | ABBVIE INC. | $12,771.76 | 05/15/2025 | Non-covered Recipient Entity INDIANA UNIVERSITY | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202485015 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $12,606.00 | 05/14/2025 | Non-covered Recipient Entity Department Of Oral And Maxillofacial Surgery And Hospital Dentistry IU Health University Hospital | Proof of Clinical Principal in Crohn???s Disease | No dispute reported | 06/30/2026 | 1220631553 |
| Principal investigator 1 | ABBVIE INC. | $33,309.12 | 05/07/2025 | Non-covered Recipient Entity INDIANA UNIVERSITY | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202482879 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $632.00 | 05/07/2025 | Covered Recipient Teaching Hospital INDIANA UNIVERSITY HEALTH | A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL | Dispute reported | 06/30/2026 | 1223266857 |
| Principal investigator 1 | ABBVIE INC. | $1,000.00 | 04/24/2025 | Non-covered Recipient Entity INDIANA UNIVERSITY | A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1202479040 |
| Principal investigator 1 | Eli Lilly and Company | $775.77 | 04/23/2025 | Non-covered Recipient Entity INDIANA UNIVERSITY | A PHASE 3, MULTICENTER, OPEN LABEL, LONG TERM EXTENSION STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH CROHNS DISEASE | No dispute reported | 06/30/2026 | 1187882290 |
| Principal investigator 1 | ABBVIE INC. | $25,593.00 | 04/17/2025 | Non-covered Recipient Entity INDIANA UNIVERSITY | A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1202477434 |
| Principal investigator 1 | ABBVIE INC. | $1,043.60 | 04/03/2025 | Non-covered Recipient Entity INDIANA UNIVERSITY | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202470999 |
| Principal investigator 1 | ABBVIE INC. | $500.00 | 03/20/2025 | Non-covered Recipient Entity INDIANA UNIVERSITY | M23-703 - A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1202465243 |
| Principal investigator 1 | ABBVIE INC. | $28,407.60 | 03/20/2025 | Non-covered Recipient Entity INDIANA UNIVERSITY | M23-784 - A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202465259 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $632.00 | 03/12/2025 | Covered Recipient Teaching Hospital INDIANA UNIVERSITY HEALTH | A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL | Dispute reported | 06/30/2026 | 1223266845 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $632.00 | 03/12/2025 | Covered Recipient Teaching Hospital INDIANA UNIVERSITY HEALTH | A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL | Dispute reported | 06/30/2026 | 1223266847 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $632.00 | 03/12/2025 | Covered Recipient Teaching Hospital INDIANA UNIVERSITY HEALTH | A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL | Dispute reported | 06/30/2026 | 1223266849 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $632.00 | 03/12/2025 | Covered Recipient Teaching Hospital INDIANA UNIVERSITY HEALTH | A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL | Dispute reported | 06/30/2026 | 1223266851 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $8.83 | 03/10/2025 | Non-covered Recipient Entity Department Of Oral And Maxillofacial Surgery And Hospital Dentistry IU Health University Hospital | Proof of Clinical Principal in Crohn's Disease | No dispute reported | 06/30/2026 | 1220994549 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $8.83 | 03/10/2025 | Non-covered Recipient Entity Department Of Oral And Maxillofacial Surgery And Hospital Dentistry IU Health University Hospital | Proof of Clinical Principal in Crohn's Disease | No dispute reported | 06/30/2026 | 1220994551 |
| Principal investigator 1 | ABBVIE INC. | $10,222.96 | 03/07/2025 | Non-covered Recipient Entity INDIANA UNIVERSITY | M23-784 - A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202461490 |
| Principal investigator 1 | ABBVIE INC. | $12,771.00 | 02/06/2025 | Non-covered Recipient Entity INDIANA UNIVERSITY | M23-784 - A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202447606 |
| Principal investigator 1 | ABBVIE INC. | $500.00 | 02/06/2025 | Non-covered Recipient Entity INDIANA UNIVERSITY | M23-703 - A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1202447609 |
| Principal investigator 1 | Eli Lilly and Company | $45,183.00 | 01/06/2025 | Non-covered Recipient Entity INDIANA UNIVERSITY | A PHASE 3, MULTICENTER, OPEN LABEL, LONG TERM EXTENSION STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH CROHNS DISEASE | No dispute reported | 06/30/2026 | 1187881488 |
| Principal investigator 1 | ABBVIE INC. | $2,657.84 | 01/02/2025 | Non-covered Recipient Entity INDIANA UNIVERSITY | M23-784 - A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202434218 |